Inovio Pharmaceuticals (INO) Change in Accured Expenses (2010 - 2026)

Inovio Pharmaceuticals has reported Change in Accured Expenses for 17 years, with the latest figure at -$1.9 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 55.29% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 7.95% YoY) and the FY2025 annual result came in at -$6.4 million, down 84.76% from the prior year.
• Change in Accured Expenses improved to -$1.9 million in Q1 2026 per INO's latest filing, from -$4.6 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $31.9 million in Q4 2022 and troughed at -$40.7 million in Q1 2023.
• A 5-year average of -$1.5 million and a median of -$1.9 million in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses surged 64808.63% in 2022, then plunged 1041.24% in 2023.
• Over 5 years, Change in Accured Expenses stood at $31.9 million in 2022, then sank by 85.42% to $4.7 million in 2023, then slumped by 81.42% to $864312.0 in 2024, then plunged by 629.34% to -$4.6 million in 2025, then soared by 59.33% to -$1.9 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.9 million, -$4.6 million, and -$350130.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.